Digital Immunohistochemistry Market

Digital Immunohistochemistry Market Analysis

The Digital Immunohistochemistry Market size is estimated at USD 686.43 million in 2025, and is expected to reach USD 942.67 million by 2030, at a CAGR of 6.55% during the forecast period (2025-2030).

Digital immunohistochemistry (IHC) is one of the most promising applications brought by new generation image analysis. Technological advancements in imaging, including high-resolution scanners and digital lab platforms, have enhanced the capabilities of digital IHC for analyzing tissue samples at a microscopic level more effectively. These advancements improve the accuracy and efficiency of diagnosis.

For instance, a study published in the Journal of Pathology Informatics in June 2022, reveals that automated estrogen receptor immunohistochemistry digital image analysis demonstrates excellent concordance with pathologist's scores and accurately discriminates estrogen receptor positive cases. Furthermore, integrating automated biomarker digital imaging analysis in immunohistochemistry into a busy clinical digital workflow is feasible and also saves time and labor for pathologists.

Moreover, manufacturers push the boundaries of innovation to meet the growing demand for digital immunohistochemistry is also a factor that drives the demand for digital immunohistochemistry. For instance, in June 2023, Aiosyn's QC solution, AiosynQC, has expanded its compatibility to include immunohistochemistry (IHC) slides, alongside its existing support for hematoxylin and eosin (H&E) slides. This enhancement not only broadens the utility of AiosynQC but also empowers laboratories heavily dependent on IHC staining to optimize their operations even further.

Thus, the validation and seamless incorporation of automated digital image analysis for immunohistochemistry into clinical workflows, coupled with companies' initiatives to transition traditional immunohistochemistry into the digital realm through the introduction of supportive digital products, are poised to propel market growth. However, complexity of integration coupled with high initial cost to set up digital lab is expected to hamper the market studied.

Digital Immunohistochemistry Market Trends

Hospital and Diagnostic Laboratories Segment is Expected to Dominant The Digital Immunohistochemistry Market during the Forecast Period

The hospital segment plays a pivotal role in the growth and adoption of the digital immunohistochemistry market. Digital immunohistochemistry refers to the digitization of traditional immunohistochemistry processes, where high-resolution images of pathology slides are captured and analyzed using specialized software. Laboratories, as critical nodes in healthcare systems, are uniquely positioned to benefit from this transition by enhancing diagnostic accuracy, efficiency, and collaboration.

The hospital and reference laboratories segment within the digital immunohistochemistry market is experiencing growth due to significant healthcare investments, increasing prevalence of cancer cases, which require effective treatment, and laboratories adopting digital platforms to perform immunohistochemistry over the study period.

The hospital segment in the digital immunohistochemistry market is experiencing growth, supported by substantial expenditure within the healthcare system. For instance, according to the Federal Ministry of Health, in 2023, total expenditure by the Statutory Health Insurance (SHI) system in Germany reached EUR 30.3 billion (USD 33.0 billion) in 2022, up from EUR 30.1 billion (USD 32.8 billion) in 2021. This significant investment underscores the robust funding allocated to hospitals and the adoption of advanced diagnostic tools like digital pathology, thereby driving the digital immunohistochemistry market growth within the hospital segment to enhancing diagnostic capabilities.

Moreover, the increasing adoption of AI-driven digital pathology integration into laboratory workflows and hospitals is expected to boost the segment’s growth. For instance, in April 2024, six NHS hospitals in the north of England, part of the West Yorkshire Association of Acute Trusts (WYAAT), adopted the National Pathology Imaging Co-operative (NPIC) digital pathology system. This system, designed for high-definition scanning and secure digital sharing of slides, marks a significant milestone in hospital-based digital laboratory.

Therefore, the hospital and reference laboratories segment is expected to grow significantly due to the increasing adoption of innovative digital pathology solutions, which will drive the segment’s growth in the digital immunohistochemistrymarket.

North america is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to witness considerable growth over the forecast period. Factors such as the growing prevalence of chronic diseases that require quick and effective diagnosis, technological advancements, adoption of digital pathology laboratories, and the presence of significant players in this region are expected to contribute to the growth of the digital immunohistochemistry market in the North American region.

For instance, in September 2024, the University Health Network (UHN) in Toronto expanded its digital laboratory capabilities to partner hospitals in northern Ontario, showcasing the system's impact on real-time diagnosis and decision-making. As more hospitals adopt digital pathology systems, the future of healthcare diagnostics will continue to evolve, improving patient outcomes and transforming hospital workflows. Thus, the adoption of digital pathology systems can streamline laboratory workflows, reduce turnaround times, and enhance operational efficiency. This optimization drives the adoption of digital immunohistochemistry solutions as part of a comprehensive digital pathology infrastructure.

Furthermore, the increasing company focus on adopting various vital strategies such as collaborations, partnerships, agreements, and product launches is expected to increase the demand and the adoption of digital immunohistochemistry product in the market. This is anticipated to fuel market growth. For instance, In March 2023, Paige integrated Mindpeak's AI algorithms, designed for immunohistochemical biomarker quantification, into its platform.

Thus, the rising adoption of digital pathology in hospitals, along with strategic partnerships formed by the players are expected to accelerate the need for robust digital laboratory solutions in the United States, and this trend is expected to accelerate market growth over the forecast period.

Digital Immunohistochemistry Industry Overview

The digital immunohistochemistry market is moderately competitive and consists of a few major players. Companies, like Danaher Corporation, Aiosyn, Vision Pharma A/S, Path AI, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc. Parhelia Biosciences and TissueGnostics GmbH among others hold substantial market shares in the digital Immunohistochemistry market.

New product developments, acquisitions, collaborations, and regional expansions are some of the key strategic initiatives undertaken by major players to maintain stability in the market.

Digital Immunohistochemistry Market Leaders

Digital Immunohistochemistry Market News

• May 2024: PathAI has unveiled two innovative AI products; PathExplore Immuno-Oncology Profiling (IOP) and Immunohistochemistry Explore1. These products be used to support biomarker discovery and the development of companion diagnostics.
• June 2022: Karkinos Healthcare has launched India's inaugural oncology laboratory, offering a full suite of cancer diagnostic services via digital platforms. This center serves as a comprehensive hub for cancer diagnostics, encompassing histopathology, Immunohistochemistry (IHC), and Fluorescence in situ hybridization (FISH), among other services.